SK272000A3 - Compounds derived from thiophene and benzothiophene, and related utilisation and composition - Google Patents
Compounds derived from thiophene and benzothiophene, and related utilisation and composition Download PDFInfo
- Publication number
- SK272000A3 SK272000A3 SK27-2000A SK272000A SK272000A3 SK 272000 A3 SK272000 A3 SK 272000A3 SK 272000 A SK272000 A SK 272000A SK 272000 A3 SK272000 A3 SK 272000A3
- Authority
- SK
- Slovakia
- Prior art keywords
- propan
- piperazin
- thiophen
- methoxyphenyl
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 37
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 title claims description 17
- 239000000203 mixture Substances 0.000 title description 34
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 title description 8
- 229930192474 thiophene Natural products 0.000 title description 3
- -1 -OR12 Chemical group 0.000 claims abstract description 26
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 23
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 16
- 150000002367 halogens Chemical class 0.000 claims abstract description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 5
- 230000036506 anxiety Effects 0.000 claims abstract description 5
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 5
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 239000012453 solvate Substances 0.000 claims description 7
- DNRNGJJWCMUHHG-UHFFFAOYSA-N 1-(3,5-dimethyl-1-benzothiophen-2-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-ol Chemical compound COC1=CC=CC=C1N1CCN(CCC(O)C2=C(C3=CC(C)=CC=C3S2)C)CC1 DNRNGJJWCMUHHG-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- VFVYVWQENQPQHA-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-one Chemical compound COC1=CC=CC=C1N1CCN(CCC(=O)C=2C3=CC=CC=C3SC=2)CC1 VFVYVWQENQPQHA-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- GZKOLGKHWMYYBA-UHFFFAOYSA-N 1-(5-fluoro-1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-ol Chemical class COC1=CC=CC=C1N1CCN(CCC(O)C=2C3=CC(F)=CC=C3SC=2)CC1 GZKOLGKHWMYYBA-UHFFFAOYSA-N 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 230000003001 depressive effect Effects 0.000 claims description 3
- WUDGDAMHAAZRGB-UHFFFAOYSA-N 1-(3,5-dimethyl-1-benzothiophen-2-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-one Chemical compound COC1=CC=CC=C1N1CCN(CCC(=O)C2=C(C3=CC(C)=CC=C3S2)C)CC1 WUDGDAMHAAZRGB-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- IYLHCRHPANQXEV-UHFFFAOYSA-N S1C2=C(C(=C1)C(CCN1CCN(CC1)C1=C(C=CC=C1)O)O)C=CC=C2.S2C1=C(C(=C2)C(CCN2CCN(CC2)C2=C(C=CC=C2)OC)O)C=CC=C1 Chemical compound S1C2=C(C(=C1)C(CCN1CCN(CC1)C1=C(C=CC=C1)O)O)C=CC=C2.S2C1=C(C(=C2)C(CCN2CCN(CC2)C2=C(C=CC=C2)OC)O)C=CC=C1 IYLHCRHPANQXEV-UHFFFAOYSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 101100212791 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YBL068W-A gene Proteins 0.000 abstract 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 239000000047 product Substances 0.000 description 26
- 238000005481 NMR spectroscopy Methods 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000000935 antidepressant agent Substances 0.000 description 10
- 229940005513 antidepressants Drugs 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- BXLSCEOVEPCFSC-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-ol Chemical compound COC1=CC=CC=C1N1CCN(CCC(O)C=2C3=CC=CC=C3SC=2)CC1 BXLSCEOVEPCFSC-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 4
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 230000000697 serotonin reuptake Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- DEOSSEJVCFYBRO-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-one;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(CCC(=O)C=2C3=CC=CC=C3SC=2)CC1 DEOSSEJVCFYBRO-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- ZQNSSVJEWSISIC-UHFFFAOYSA-N 3-[4-(2-methoxyphenyl)piperazin-1-yl]-1-(5-nitro-1-benzothiophen-3-yl)propan-1-one;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(CCC(=O)C=2C3=CC(=CC=C3SC=2)[N+]([O-])=O)CC1 ZQNSSVJEWSISIC-UHFFFAOYSA-N 0.000 description 3
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 3
- 150000002923 oximes Chemical class 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 3
- JJYKJUXBWFATTE-UHFFFAOYSA-N (+)-(S)-MTPA chloride Natural products COC(C(O)=O)(C(F)(F)F)C1=CC=CC=C1 JJYKJUXBWFATTE-UHFFFAOYSA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- JEQDSBVHLKBEIZ-REOHCLBHSA-N (2s)-2-chloropropanoyl chloride Chemical compound C[C@H](Cl)C(Cl)=O JEQDSBVHLKBEIZ-REOHCLBHSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 2
- SAKMPBZMKJNAQP-UHFFFAOYSA-N 1-(3,5-dimethyl-1-benzothiophen-2-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-one;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(CCC(=O)C2=C(C3=CC(C)=CC=C3S2)C)CC1 SAKMPBZMKJNAQP-UHFFFAOYSA-N 0.000 description 2
- WBXQIAKHNGXXCJ-UHFFFAOYSA-N 1-(4-fluoro-2-methoxyphenyl)piperazine Chemical compound COC1=CC(F)=CC=C1N1CCNCC1 WBXQIAKHNGXXCJ-UHFFFAOYSA-N 0.000 description 2
- HKYGFPKEWJLLIH-UHFFFAOYSA-N 1-(5-amino-1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-one;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCC(=O)C=2C3=CC(N)=CC=C3SC=2)CC1 HKYGFPKEWJLLIH-UHFFFAOYSA-N 0.000 description 2
- ZDMMLPUNHWVPTB-UHFFFAOYSA-N 1-(5-chloro-1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-ol Chemical compound COC1=CC=CC=C1N1CCN(CCC(O)C=2C3=CC(Cl)=CC=C3SC=2)CC1 ZDMMLPUNHWVPTB-UHFFFAOYSA-N 0.000 description 2
- NEGNBHLPJFCWGS-UHFFFAOYSA-N 1-(5-chloro-1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-ol;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCC(O)C=2C3=CC(Cl)=CC=C3SC=2)CC1 NEGNBHLPJFCWGS-UHFFFAOYSA-N 0.000 description 2
- YZWRRZVMSWDFGO-UHFFFAOYSA-N 1-(5-chloro-1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-one;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(CCC(=O)C=2C3=CC(Cl)=CC=C3SC=2)CC1 YZWRRZVMSWDFGO-UHFFFAOYSA-N 0.000 description 2
- VYFUKRPJLFKBHB-UHFFFAOYSA-N 1-(5-fluoro-1-benzothiophen-3-yl)-3-[4-(2-methoxyphenyl)piperazin-1-yl]propan-1-ol;dihydrochloride Chemical compound Cl.Cl.COC1=CC=CC=C1N1CCN(CCC(O)C=2C3=CC(F)=CC=C3SC=2)CC1 VYFUKRPJLFKBHB-UHFFFAOYSA-N 0.000 description 2
- GUWLBGGBIKBCDQ-UHFFFAOYSA-N 1-(5-methyl-1-benzothiophen-3-yl)ethanone Chemical compound C1=C(C)C=C2C(C(=O)C)=CSC2=C1 GUWLBGGBIKBCDQ-UHFFFAOYSA-N 0.000 description 2
- ABYMPOVMMYXTTE-UHFFFAOYSA-N 2-[4-[3-(1-benzothiophen-3-yl)-3-hydroxypropyl]piperazin-1-yl]phenol Chemical compound C=1SC2=CC=CC=C2C=1C(O)CCN(CC1)CCN1C1=CC=CC=C1O ABYMPOVMMYXTTE-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- CBICHJHISQKQLU-UHFFFAOYSA-N 3-[4-(2-methoxyphenyl)piperazin-1-yl]-1-(3-methyl-1-benzothiophen-2-yl)propan-1-ol Chemical compound COC1=CC=CC=C1N1CCN(CCC(O)C2=C(C3=CC=CC=C3S2)C)CC1 CBICHJHISQKQLU-UHFFFAOYSA-N 0.000 description 2
- HHSTVLXUFAQPPK-UHFFFAOYSA-N 3-[4-(2-methoxyphenyl)piperazin-1-yl]-1-(3-methyl-1-benzothiophen-2-yl)propan-1-one;hydrochloride Chemical compound Cl.COC1=CC=CC=C1N1CCN(CCC(=O)C2=C(C3=CC=CC=C3S2)C)CC1 HHSTVLXUFAQPPK-UHFFFAOYSA-N 0.000 description 2
- MHQFRPFBJOEPGE-UHFFFAOYSA-N 4-fluoro-2-methoxyaniline;hydrochloride Chemical compound Cl.COC1=CC(F)=CC=C1N MHQFRPFBJOEPGE-UHFFFAOYSA-N 0.000 description 2
- NOVKHIQVXQKSRL-UHFFFAOYSA-N 5-nitro-1-benzothiophene Chemical compound [O-][N+](=O)C1=CC=C2SC=CC2=C1 NOVKHIQVXQKSRL-UHFFFAOYSA-N 0.000 description 2
- ZGSMHACHDULBBY-UHFFFAOYSA-N 5-nitro-1-benzothiophene-2-carboxylic acid Chemical compound [O-][N+](=O)C1=CC=C2SC(C(=O)O)=CC2=C1 ZGSMHACHDULBBY-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- DFGBQJHVCMFVID-UHFFFAOYSA-N ethyl 5-nitro-1-benzothiophene-2-carboxylate Chemical compound [O-][N+](=O)C1=CC=C2SC(C(=O)OCC)=CC2=C1 DFGBQJHVCMFVID-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- PAORVUMOXXAMPL-VIFPVBQESA-N (2r)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-VIFPVBQESA-N 0.000 description 1
- HQRSIMQXCAWAJB-SSDOTTSWSA-N (2r)-3,3,3-trifluoro-2-phenylpropanoic acid Chemical compound OC(=O)[C@H](C(F)(F)F)C1=CC=CC=C1 HQRSIMQXCAWAJB-SSDOTTSWSA-N 0.000 description 1
- HLPRFTBLOBPJLF-ZETCQYMHSA-N (2r)-3,3,3-trifluoro-2-phenylpropanoyl chloride Chemical compound FC(F)(F)[C@H](C(Cl)=O)C1=CC=CC=C1 HLPRFTBLOBPJLF-ZETCQYMHSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KUKSPRRZVLBAEX-QMMMGPOBSA-N (2s)-2-methoxy-2-phenylacetyl chloride Chemical compound CO[C@H](C(Cl)=O)C1=CC=CC=C1 KUKSPRRZVLBAEX-QMMMGPOBSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical group C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- KTZQTRPPVKQPFO-UHFFFAOYSA-N 1,2-benzoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- LVOATWHQZMBRPB-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-[4-(2-hydroxyphenyl)piperazin-1-yl]propan-1-one;hydrochloride Chemical compound Cl.OC1=CC=CC=C1N1CCN(CCC(=O)C=2C3=CC=CC=C3SC=2)CC1 LVOATWHQZMBRPB-UHFFFAOYSA-N 0.000 description 1
- CFZNICPWSJXJJO-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-[4-(4-fluoro-2-methoxyphenyl)piperazin-1-yl]propan-1-ol;hydrochloride Chemical compound Cl.COC1=CC(F)=CC=C1N1CCN(CCC(O)C=2C3=CC=CC=C3SC=2)CC1 CFZNICPWSJXJJO-UHFFFAOYSA-N 0.000 description 1
- CDRVOYUYGCKVLE-UHFFFAOYSA-N 1-(1-benzothiophen-3-yl)-3-[4-(4-fluoro-2-methoxyphenyl)piperazin-1-yl]propan-1-one;hydrochloride Chemical compound Cl.COC1=CC(F)=CC=C1N1CCN(CCC(=O)C=2C3=CC=CC=C3SC=2)CC1 CDRVOYUYGCKVLE-UHFFFAOYSA-N 0.000 description 1
- DDMVHGULHRJOEC-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazin-1-ium;chloride Chemical compound Cl.COC1=CC=CC=C1N1CCNCC1 DDMVHGULHRJOEC-UHFFFAOYSA-N 0.000 description 1
- HQALDKFFRYFTKP-UHFFFAOYSA-N 2-[4-[4-(2-benzyl-1-benzothiophen-3-yl)phenyl]-2-bromo-6-(3-methoxyphenyl)phenoxy]acetic acid Chemical compound COC1=CC=CC(C=2C(=C(Br)C=C(C=2)C=2C=CC(=CC=2)C=2C3=CC=CC=C3SC=2CC=2C=CC=CC=2)OCC(O)=O)=C1 HQALDKFFRYFTKP-UHFFFAOYSA-N 0.000 description 1
- VFVHWCKUHAEDMY-UHFFFAOYSA-N 2-chloro-5-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(Cl)C(C=O)=C1 VFVHWCKUHAEDMY-UHFFFAOYSA-N 0.000 description 1
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- GHSAINDQNSICDQ-UHFFFAOYSA-N 3-[4-(2-hydroxyphenyl)piperazin-1-yl]-1-(3-methyl-1-benzothiophen-2-yl)propan-1-one;hydrochloride Chemical compound Cl.S1C2=CC=CC=C2C(C)=C1C(=O)CCN(CC1)CCN1C1=CC=CC=C1O GHSAINDQNSICDQ-UHFFFAOYSA-N 0.000 description 1
- DYWRDLBMWOHXSY-UHFFFAOYSA-N 3-chloro-1-(5-nitro-1-benzothiophen-3-yl)propan-1-one Chemical compound [O-][N+](=O)C1=CC=C2SC=C(C(=O)CCCl)C2=C1 DYWRDLBMWOHXSY-UHFFFAOYSA-N 0.000 description 1
- WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- DOHZWDWNQFZIKH-UHFFFAOYSA-N 5-methyl-1-benzothiophene Chemical compound CC1=CC=C2SC=CC2=C1 DOHZWDWNQFZIKH-UHFFFAOYSA-N 0.000 description 1
- 102000007527 Autoreceptors Human genes 0.000 description 1
- 108010071131 Autoreceptors Proteins 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 101000841267 Homo sapiens Long chain 3-hydroxyacyl-CoA dehydrogenase Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- 102100029107 Long chain 3-hydroxyacyl-CoA dehydrogenase Human genes 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101100011512 Rattus norvegicus Elovl6 gene Proteins 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940070023 iproniazide Drugs 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- FBBDOOHMGLLEGJ-UHFFFAOYSA-N methane;hydrochloride Chemical compound C.Cl FBBDOOHMGLLEGJ-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- UNEIHNMKASENIG-UHFFFAOYSA-N para-chlorophenylpiperazine Chemical compound C1=CC(Cl)=CC=C1N1CCNCC1 UNEIHNMKASENIG-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
- JOCYRIINDHNKNL-UHFFFAOYSA-N propanal;dihydrochloride Chemical compound Cl.Cl.CCC=O JOCYRIINDHNKNL-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000011946 reduction process Methods 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
- C07D333/44—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms attached in position 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009701517A ES2128266B1 (es) | 1997-07-08 | 1997-07-08 | Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes. |
PCT/ES1998/000191 WO1999002516A1 (es) | 1997-07-08 | 1998-07-01 | Compuestos derivados de tiofeno y benzotiofeno y utilizacion y composicion correspondientes |
Publications (1)
Publication Number | Publication Date |
---|---|
SK272000A3 true SK272000A3 (en) | 2000-07-11 |
Family
ID=8299986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK27-2000A SK272000A3 (en) | 1997-07-08 | 1998-07-01 | Compounds derived from thiophene and benzothiophene, and related utilisation and composition |
Country Status (21)
Country | Link |
---|---|
US (1) | US6262056B1 (ja) |
EP (1) | EP1008594B1 (ja) |
JP (1) | JP2002511883A (ja) |
KR (1) | KR20010021632A (ja) |
CN (1) | CN1125821C (ja) |
AT (1) | ATE261956T1 (ja) |
AU (1) | AU735637B2 (ja) |
BR (1) | BR9810557A (ja) |
CA (1) | CA2295715A1 (ja) |
DE (1) | DE69822478D1 (ja) |
EA (1) | EA002687B1 (ja) |
ES (1) | ES2128266B1 (ja) |
HU (1) | HUP0002861A3 (ja) |
IL (1) | IL133566A (ja) |
IS (1) | IS5328A (ja) |
NZ (1) | NZ502128A (ja) |
OA (1) | OA11274A (ja) |
PL (1) | PL337930A1 (ja) |
SK (1) | SK272000A3 (ja) |
TR (1) | TR200000058T2 (ja) |
WO (1) | WO1999002516A1 (ja) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6050500A (en) * | 1999-07-21 | 2001-02-13 | Eli Lilly And Company | Benzothiophene derivatives |
CZ20022319A3 (cs) * | 1999-12-30 | 2002-10-16 | H. Lundbeck A/S | Substituovaná fenylpiperazinová sloučenina a farmaceutický prostředek, který ji obsahuje |
DE10043659A1 (de) * | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | Arylpiperazinderivate |
ES2188344B1 (es) * | 2000-11-29 | 2004-09-16 | Laboratorios Vita, S.A. | Compuestos derivados de benzotiofeno, su procedimiento de obtencion y utilizacion de los mismos. |
PL378369A1 (pl) | 2003-01-13 | 2006-04-03 | Dynogen Pharmaceuticals, Inc. | Sposób leczenia mdłości, wymiotów, nudności lub ich dowolnej kombinacji |
WO2004082686A2 (en) * | 2003-03-13 | 2004-09-30 | Dynogen Pharmaceuticals, Inc. | Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction |
TWI320783B (en) | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
CA2686547C (en) * | 2007-05-14 | 2015-12-08 | Sk Holdings Co., Ltd. | Novel carbamoyloxy aryl alkan arylpiperazine compound, pharmaceutical compositions comprising the compound and method for treating pain, anxiety and depression by administering the compound |
CN101613347B (zh) * | 2008-06-23 | 2012-07-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 胺类化合物及其医药用途 |
CN101619056B (zh) * | 2008-07-02 | 2013-07-17 | 石药集团中奇制药技术(石家庄)有限公司 | 苯并噻吩烷醇哌嗪衍生物及其作为抗抑郁症药物的应用 |
EP2539706B1 (en) * | 2010-02-24 | 2015-03-04 | Research Triangle Institute | Arylpiperazine opioid receptor antagonists |
US9714232B2 (en) | 2013-12-20 | 2017-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted piperazine compounds and methods of use thereof |
WO2021152113A1 (en) | 2020-01-31 | 2021-08-05 | Bayer Aktiengesellschaft | Substituted 2,3-benzodiazepines derivatives |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2979507A (en) * | 1959-03-26 | 1961-04-11 | Paul Adriaan J Janssen | 1-(2-thenoyl) alkyl-4-arylpiperazines |
US3002976A (en) * | 1959-10-12 | 1961-10-03 | Paul A J Janssen | 1-(2-thienyl)-omega-(4-arylpiperazine)alkanols |
GB1096341A (en) * | 1965-03-09 | 1967-12-29 | Mauvernay Roland Yves | Novel derivatives of the phenyl-piperazine series and process for their preparation |
US4515793A (en) * | 1983-07-27 | 1985-05-07 | Edna Mcconnell Clark Foundation | Phenylpiperazines which are useful in the treatment of schistosomiasis |
WO1993003025A1 (fr) * | 1991-08-09 | 1993-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thiophene |
FR2692264B1 (fr) * | 1992-06-12 | 1994-08-05 | Adir | Nouvelles piperazines 1,4-disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
US5632898A (en) * | 1996-08-13 | 1997-05-27 | Isis Pharmaceuticals, Inc. | Method for removing unreacted electrophiles from a reaction mixture |
-
1997
- 1997-07-08 ES ES009701517A patent/ES2128266B1/es not_active Expired - Fee Related
-
1998
- 1998-07-01 BR BR9810557-4A patent/BR9810557A/pt not_active IP Right Cessation
- 1998-07-01 CA CA002295715A patent/CA2295715A1/en not_active Abandoned
- 1998-07-01 AU AU81113/98A patent/AU735637B2/en not_active Ceased
- 1998-07-01 EP EP98930807A patent/EP1008594B1/en not_active Expired - Lifetime
- 1998-07-01 AT AT98930807T patent/ATE261956T1/de not_active IP Right Cessation
- 1998-07-01 KR KR1020007000190A patent/KR20010021632A/ko not_active Application Discontinuation
- 1998-07-01 CN CN98807490A patent/CN1125821C/zh not_active Expired - Fee Related
- 1998-07-01 HU HU0002861A patent/HUP0002861A3/hu unknown
- 1998-07-01 TR TR2000/00058T patent/TR200000058T2/xx unknown
- 1998-07-01 NZ NZ502128A patent/NZ502128A/en unknown
- 1998-07-01 WO PCT/ES1998/000191 patent/WO1999002516A1/es not_active Application Discontinuation
- 1998-07-01 PL PL98337930A patent/PL337930A1/xx unknown
- 1998-07-01 JP JP50819399A patent/JP2002511883A/ja active Pending
- 1998-07-01 DE DE69822478T patent/DE69822478D1/de not_active Expired - Lifetime
- 1998-07-01 IL IL13356698A patent/IL133566A/xx not_active IP Right Cessation
- 1998-07-01 EA EA200000101A patent/EA002687B1/ru not_active IP Right Cessation
- 1998-07-01 SK SK27-2000A patent/SK272000A3/sk unknown
-
1999
- 1999-12-29 IS IS5328A patent/IS5328A/is unknown
-
2000
- 2000-01-06 OA OA1200000002A patent/OA11274A/en unknown
- 2000-01-10 US US09/480,120 patent/US6262056B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1008594A1 (en) | 2000-06-14 |
HUP0002861A2 (hu) | 2001-08-28 |
HUP0002861A3 (en) | 2001-09-28 |
WO1999002516A1 (es) | 1999-01-21 |
ES2128266B1 (es) | 2000-01-16 |
EA002687B1 (ru) | 2002-08-29 |
CN1265106A (zh) | 2000-08-30 |
AU735637B2 (en) | 2001-07-12 |
KR20010021632A (ko) | 2001-03-15 |
IL133566A0 (en) | 2001-04-30 |
ES2128266A1 (es) | 1999-05-01 |
CN1125821C (zh) | 2003-10-29 |
AU8111398A (en) | 1999-02-08 |
IL133566A (en) | 2003-10-31 |
ATE261956T1 (de) | 2004-04-15 |
OA11274A (en) | 2003-07-29 |
BR9810557A (pt) | 2000-08-08 |
PL337930A1 (en) | 2000-09-11 |
NZ502128A (en) | 2001-09-28 |
IS5328A (is) | 1999-12-29 |
EA200000101A1 (ru) | 2000-08-28 |
TR200000058T2 (tr) | 2000-09-21 |
US6262056B1 (en) | 2001-07-17 |
DE69822478D1 (de) | 2004-04-22 |
CA2295715A1 (en) | 1999-01-21 |
EP1008594B1 (en) | 2004-03-17 |
JP2002511883A (ja) | 2002-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1337528B1 (en) | Benzothiophene derivative compounds, process of preparation and use thereof | |
KR0156910B1 (ko) | 프로페논 옥심 에테르, 그의 제조방법 및 그를 함유하는 약학적 조성물 | |
SK272000A3 (en) | Compounds derived from thiophene and benzothiophene, and related utilisation and composition | |
WO2008081476A2 (en) | Process for preparing duloxetine hydrochloride | |
US4024156A (en) | Thiophene ethanolamines | |
EP0543584B1 (en) | Benzo(b)thiophene-2-carboxamides for the treatment of disorders of the central nervous system | |
DK160043B (da) | Analogifremgangsmaade til fremstilling af n-alk-2-en-4-yn-yl-benzothienylalkylaminer eller syreadditionssalte deraf | |
US6417222B1 (en) | [2-substituted-5-[3-thienyl)-benzyl]-2- ([2-isopropoxy-5-fluoro]-phenyoxy)-ethyl]-amine derivatives, method for the production and use thereof as medicaments | |
CZ479499A3 (cs) | Deriváty benzothiofenu, použití a přípravky | |
JPH04266888A (ja) | 製薬化合物 | |
NZ230628A (en) | Ring-substituted alkylene amine derivatives, preparatory intermediates and pharmaceutical compositions | |
MXPA00000351A (en) | Compounds derived from thophene and benzothiophene, and related utilisation and composition | |
Namil et al. | Synthesis of 4-N, N-dialkylaminoethyl-2-indolones as potential dopamine agonists | |
JPS6251264B2 (ja) |